We did an internal experiment using LLMs to parse and visualise ORRs from AACR clinical trial abstracts. Worked pretty well; check out the results in the link (click the bubbles to open the relevant abstract)

aacr.convoke.bio

Amylyx $AMLX to pull ALS drug from market, cut 70% of staff statnews.com/2024/04/04/amy… via Allison DeAngelis

News aside, I have deep respect for the way Josh and Justin have handled the Relyvrio situation. A lot of companies talk about prioritizing patients over business. Amylyx…

We're so back (in SF). I'll be here until end of May; if you're in biotech/tech/techbio we should meet up!

Don't think I've seen complementary blood cell banking used as a way to attract shareholders before

Any docs here use Doximity or Sermo? Do you find them useful?

$REGN - FDA rejected odronextamab, its CD20xCD3 bispecific antibody for follicular lymphoma and DLBCL.

'The only approvability issue is related to the enrollment status of the confirmatory trials.'

Some imaginative ideas here, hope to see them written. Even though the link is 'just' a list of articles it's a good read

Good visual to build intuition on why nanopore protein sequencing is a harder technical challenge than (mostly solved) DNA/RNA nanopore sequencing

Why has menopause become a normal part of every woman's life, when it causes unnecessary suffering?

Why is reproductive aging research still significantly underfunded when half of the population experiences menopause?

I believe this *needs* to change, so I wrote a piece about…

preclinical disease model dev is ripe for a focused research org

- huge but diffuse rewards
- too basic & exploratory for most biotechs
- poorly incentivized in academia + too large scale
- natural exit path to a sustainable business (model licensing/services)

Come work with me!

DM/email me if you're a software developer who wants to solve interesting problems in biotech using automation & LLMs. Open to informal/exporatory chats too, even if you're just curious